Novo Nordisk : Results penalised by GLP1s in diabetes; Wegovy reassuring
>GLP1s prescribed in diabetes treatments fell short of expectations - Novo Nordisk this morning reported Q3 2024 results that fell short of expectations at the sales level but which were in line on the margin thanks to good control of costs: -1.5% below expectations for the top line (DKK 71.3bn, +21%) but +0.5% above for EBIT (DKK 33.8bn, +26%). The GLP-1 franchise in diabetes was strongly penalised by Victoza. GLP-1s were mainly affected by negative adjustments ...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.